PD
MGX icon

Point72 (DIFC)’s Metagenomi Therapeutics MGX Stock Holding History

Point72 (DIFC)’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$318 Hold
134
– – ﹤0.01% 1101
2025
Q2 		$198 Buy
+134
New +$210 ﹤0.01% 1481
2024
Q4 		– Sell
-97
Closed -$210 – 1967
2024
Q3 		$210 Sell
97
-2,198
-96% -$7.63K ﹤0.01% 1359
2024
Q2 		$9.36K Buy
+2,295
New +$15.8K ﹤0.01% 1317

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Point72 (DIFC)'s MGX Position: Q3 2025 in Review

Point72 (DIFC) held its Metagenomi Therapeutics (MGX) position steady in Q3 2025 at 134 shares worth $318. The position accounts for ﹤0.01% of the portfolio, ranked #1101.

Point72 (DIFC) first reported a position in MGX in Q2 2024 and has held it in 4 quarters since. The position peaked at $9.36K in Q2 2024. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Point72 (DIFC) held 134 shares of Metagenomi Therapeutics worth $318 as of Q3 2025.
  • Point72 (DIFC) left its Metagenomi Therapeutics share count unchanged in Q3 2025.
  • Metagenomi Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1101 holding.
  • Point72 (DIFC) first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Point72 (DIFC)'s Metagenomi Therapeutics position peaked at $9.36K in Q2 2024.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.